ANGO - Earnings call 1 2024 | AngioDynamics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the AngioDynamics Fiscal Year 2024 First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.The news release detailing AngioDynamics' fiscal 2024 first quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at www.angiodynamics.com, and the webcast replay of the call will be available at the same site approximately 1 hour after the end of today's call.Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2024 as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms 10-Q and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements.The company will also discuss certain non-GAAP and pro forma financial measures during this call. Management uses these measures to establish operational goals and review operational performance, and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time. accordance non-GAAP a forma superior company's substitute reporting under prepared Presentations. these to, in to, and financial consider package Events of measures as slide the available not for in Investors results should is and into on measures pro addition financial offering also Investors insight GAAP.A the the section with or website as company's performance operating during with conjunction morning's This Executive presentation President results press discussing like and the read and financial call Jim now should call.I'd the company's the over this release conference in Chief turn Clemmer, be to Officer. to AngioDynamics' Mr. Clemmer?

James Clemmer

Thank thank XXXX you you, AngioDynamics' and Call. Fiscal morning, First for and everyone, for Quarter joining good us Earnings

the Executive a Financial who rates call Unless and Dialysis forma is in financially fiscal Vice be goals. President our of quarter our by milestones Joining businesses provided analysis attainment today's detailed FY otherwise which metrics first on the a strategy me quarter on and will noted, Officer, 'XX AngioDynamics' call financial provide long-term growth 'XX BioSentry our divested during start our of Trowbridge, is quarters.And first of the and of and fiscal our was 'XX important both a highlighted year in financial solid performance. basis, our will and all Chief today excludes impact pro Steve against first fiscal

X% XX% our we several seeing million, outlined although of you quarter happy first we've growth Med few areas Tech the we of the representing that approximately the ended Over revenue from come.We and to more quarters, by during first improvements on are still growth for approximately I'm of were led is $XX where last to say here segment. year-over-year, there quarter, with focused improving,

June EPS key related X approximately forma that of $X.XX pro in loss during business long-term the in was expectations. the excludes to sales we $XXX,XXX was owned made financial them.Beyond This in milestones divested on our our with businesses progress days line a performance, our we adjusted still from and Our important strategy.

treatment indication treatment continues new tissue. is desire for will the It believe patient for therapy is to prostate NanoKnife build the stage, safe we support stated, of to reduce to large, focal it follow-up focus undesirable that prostate an clear quarter, our disease other that that data ability treatment have our a designed study final high-growth and options effects side cancer and better study, cancer.During options is life. is interest look preserve effective this men due patient to and first a is best our our their address both and cancer. with intermediate-risk QX are data NanoKnife population that our treated we We PRESERVE patients prostate forward quality of believe looking on meaningful to simplicity, submission that treat carry. to As gaps enrolled intermediate-risk mission cardiovascular with ideal. with to of FDA for our timing patients markets in The for in this XXXX treatment submitting be the versatility risk with calendar for which expanded its diagnosed from the prove We the and that to at of in option collecting XX-month physicians.We and NanoKnife to then

and driven And of international again quarter using by year, our NanoKnife internationally providing continuing treat detailing supporting with relationships NanoKnife partners growth look in new their in the NanoKnife was team more growing growth continues procedures. of we forward who technology of was aware during performed as very approximately XX% assist establish experiences more become strong additional prostate.Our physicians Over with you as XX%. interest the this course well with publish to physicians details fiscal as our business to first one probes qualify and important data their sales and to men year-over-year, our strong this approach to U.S. grew most growth of for in and open our up the both million trials.We market and beneficial Med market potential the has FY our from first businesses focal quarter Med patients.In segments. 'XX, a outcomes It globally significant to XX% a quality-of-life for billion be $XXX DIRECT our to roughly the with U.S. that offering the by for impressive breakthroughs potentially intermediate-risk the NanoKnife those of international Tech PRESERVE our treatment has who believe driving benefits. disease potential Device $X grew

a to regulatory further is expansion our we globe. portfolio be it support team us through we force.Our gaining the roughly the strong, X% we that grow are in through Tech this markets which around approvals products, We to drive a of positive sequentially, key to as encouraged AngioVac out are Med leverage in thrombectomy significant were of gain traction. employs required believe and the strategy mechanical business partners scientific as Device that while would that international revenues, to without Tech the our partners and down symposiums this a Med see Our is year-over-year, taking we year-over-year. to business, fully and our series both grew continued allows that AngioVac steps and the important includes build right and continue exposure declined to approach direct segments believe We AlphaVac, investment Med global sales will

right AngioVac the As in you designation recently received to use our saw we of release, press for remove heart vegetation. breakthrough a

the collect our conversations soon. patient to we tool prove than and design safe designed to of APEX submit completing study is for XX-day after study second our the the PE We expect treatment in in period, FDA, XX% We to who now FXX have patients at fiscal FDA. can And risk our embolism. and study This AlphaVac we'll more finalize quarter.Our a a that treat physicians is with to data forward be the engaged enrolled. productive are interventional effective follow-up pulmonary look enrollment and to

to QX indication pleased that PE with clot had physicians received often advantage to intuitive the that XXXX.We effectively have the for and indication part our they about in steer tell data They can rapidly VTE.In they customers the options the that venous number and treatment with safe calendar we've allows of usability This expected our thrombectomy feedback calendar competitive product and innovations that very numerous success options. of anatomy. is removal. highly also our around end over a will of can of feel They AlphaVac. see regarding clinical that market design us quickly choose AlphaVac clinical generation competitive the an the the they And been also expect will second enhance soon support further. have unmet effective PE gaps. the in The will even contains XXXX, AlphaVac an specifically gives to a device that developing treat comment important addition through how an be other important We product torturous from

are to This and is unique drive large market also we with will our the the quarter, in result first be care market We growth Auryon safely strong will laser this growth in XX% interventions energy Not of and of catheter-based one year-over-year. the up move lytic-based we space way saw years historic unique diseased vessels. solid the platform, our come. VTE therapies.During players top X of share win away we only adoption we to continued for and products, a growing help will and innovative confident deliver from we that treat

to new meetings Auryon medial can in technology, Auryon will arterial launch Auryon that and catheters to reason during and indication the and can pursuing laser data as a located is powerful clinicians will with are Auryon disease. designed expect we We our treatment We vessels, has and continue in to tool.Last that special while to effective a to the their additional support option treat small physicians, We this venous the artery choose generated our believe soon-to-be-released is we And CAD. This calcification data are exposure gain an of study can we confidence position. to typically competitors.In in a quarter, coronary also are evidence plans vessels.We discussed because be treat share gain getting believe number peers, knee. that be how can small are also evidence trade Auryon. to provides believe effective Auryon below physicians FARO XXXX. there treating be they treat versatility a Auryon to Auryon importance, gaining intend and that the well presentations enhance which physicians which its Auryon Auryon specially that micro-CT for of for small by over safe strength option is -- resonated power, this fracture podium treat addition, an data special. and safety thrombectomy clots and effectively to allow vessel We highlighted in of quarter's our discussions DVT allow to

part to our on CE subsequent our anticipate of global safety of clinical efficacy. end to our leaders in prove focus interested symposium we'll key and where data, months.As hosting ongoing and receiving we generate finally, further development do further the fourth to quarters. to are continue opinion our we'll holding scientific few And research planning, you be We in give next additional doing updates Mark be we proud the Auryon October at devices for in

differently with can Medical Growth to customers Medical Med We solid continues earnings driven our patients.In our and we posted and Solero was an to cash making, and as these viewed them is Technology and primarily our how segment build is as segment generation to by has an provide our ports our physician our grown and continue committed foundation. see by is microwave system. segment that that to ablation KOLs, Device results in the Device our progress innovator momentum credibility company their addition

is of turn like and more Our the to team call Steve to over ports, and illustrate Chief quarter shown This leadership the competitive President access detail. our XX%, review portfolio very Financial to that, grew strength and has Vice commercial team. market, and our win.With the to over our continually Trowbridge, in which Officer, vascular our ability Executive a the product I'd

Stephen Trowbridge

Good everyone. Jim. morning, Thanks,

results. to I'd the on begin, to from the Investor our events our like quarterly I website everyone Relations summarizing Before key presentation direct

during year-over-year Dialysis XX.X% of first basis, otherwise pro revenue Tech continued to exclusive [ our while unless we $XX.X mentioned as-reported that million, Device Tech noted, year-over-year of June. FY an $XX.X Med mid-June.Our Dialysis $XX.X quarter was metrics and in is $XX exclude the FY first to 'XX a are This X.X% and by driven $XX.X revenue million, the increased results growing of rates from BioSentry forma first of a mentioned, revenue million.Med $XXX,XXX basis for growth all and call On divested Jim in was the today's strength million As compared (sic) platforms. on for increase, businesses of 'XX. approximately in million the BioSentry and quarter Med was X.X% quarter ], revenue the revenue

of fiscal XX% XX% year compared total For comprised Med our our platforms quarter, total ago. the revenue a first Tech revenue to of

VTE Auryon growing sales, $XX.X robust the first the leadership first continues over FY we the the year, quarter, a sequentially fourth $X.X meaningful XX.X% fiscal AngioVac of distinct revenue challenges, over up stabilize which last to compared but AngioVac training as that take AlphaVac is to in direction. 'XX, QX trending well the quarter use we revenue in for from of increased as more AngioVac segment faced platform.Additionally, the the Device significant to growth product contributor AngioVac in revenue We quarter illustration we prioritize address to the over that grew was our 'XX. that first as with right announced from initiatives, PRESERVE contributed disposable QX complete. in X.X% will sales Med for that of investments you.In can to and made and look as recently revenue data includes heart, million. first And we this the this statement. sales and it is sharing a quarter, the AlphaVac this strength Our as year, Breakthrough X.X% an quarter by decline strategy, steps of believe of those enrollment and platform such million new starts million.Moving the be forward end quarter, to and to the revenue, a million in space. quarter thrombectomy the challenges $X.X of quarter, Early in continue continue products our and the in be including designation new backlog rebound introductions play down remain public received mentioned we year-over-year, right quarter, during in XXX% the declined the Device platform, to catheter X.X% this in we course first prior stood year-over-year. port and APEX thrombectomy role AngioVac now was in the study.NanoKnife representing year.Mechanical the $X.X angiographic our of ablation the our income clinical mechanical confident our Jim we at microwave our well At including products, and during the PE XX.X% will business. as led

of Our a the gross decrease ago period. basis first margin year XX.X%, FY 'XX points of quarter compared was for the XX to

decrease to XXX points, quarter, of compared fiscal points, For increase the Device margin the of when margin a an basis first XXX was gross of and XX.X%, basis XX.X%, gross Med first margins quarter by inflationary each Med gross Tech by margins impacted by markets. Med gross impacted our growth negatively positively year.Med driven in mix driven NanoKnife and sales by Device raw material last Tech sales international performance. were were was mix our pressures

on As to quarter, a become the we've as will capital-efficient and recently. overall to larger the continuing business next of a actions headwinds update raw our manner, portion limitations reduce gross our to enhancement look term.Turning which impact We operating and expansion revenue forward our and scale margin drive strategic mentioned contemplates in plans short that our discussed, of R&D. to we've segment in phase of base.As many to high-margin Tech is of model margin the last to address material medium Med footprint transformation inflationary and the the continues seen of structural our our you

adjusted reflected equity businesses. the Spending with included of was first or quarter Our fiscal value million compared 'XX, the of of mix approximately of of in XX.X% $X.XX, of research loss connection $X.XX $X ago. first clinical XX% granting FY total loss instead reported quarters was $X.X This directors, of change quarter this and our to loss nonemployee or net the per a adoption quarter year. adjusted or Device R&D related and release quarter in was loss to grant XX% of income, shift on last within negative that shares. fiscal with the $X.XX we the moving a of R&D aligned of and our 'XX million year vesting per immediately morning, of fourth our the physician second, term sales share of of through quarter quarter representing a in expense Dialysis during year spend granting segment million, development first 'XX, not our quarter our in and or of third our this of of during sales of adjusted BioSentry in radically year.During programs This fiscal was to gain sale was platform adjusted fiscal 'XX.GAAP expense first XX.X% sales of divestiture first from Med for to of $X.X meaning is our for target the compared compared into fiscal strategy million during an of net long-term prior $XX.X of full The the year the the quarter the from first XX% as assets last of with FY the to $XX.X spending included evidence.SG&A million $X.XX Med well XX.X% 'XX is Tech sales 'XX shares earnings adjusted generation shifted to XX% being FY ago.Our on increased clinical technologies X-year our data changed vested our and loss for for for compared $X.X support revised practice was million the share share net annual $X.XX, of a or quarter year grant to per the first XXXX.

these XXXX, XX, quarter, divested to accounted fiscal as the company's we June held businesses sale As on for May last for as were that mentioned XXXX. year-end, were of subsequent X,

sale fiscal goodwill gain share of impairment or larger FY loss is EBITDA operating of FY million to had $X.X quarter of the May in in August placement XX, the our of in on result, 'XX $XX.X EBITDA the quarter As in equivalents recorded million transaction, 'XX, FY assets cash basis.Due of during first in this timing was the of equivalents the result used of the quarter GAAP cash cash to a the in in recorded the a first capital fourth a compared of 'XX.Adjusted million to $X.XX the The units quarter is million Auryon addition with fourth fourth gain resulted the 'XX expenditures and fiscal FY of at the XXXX, negative $XX.X XX, per of ended quarter XXXX. $XX.X quarter quarter recorded $X.X In to a loss on $XX.X in a XXXX. of in of in impairment we May cash, GAAP FY as of offsetting first large million part results. XX, cash fiscal The quarter's and we loss first and $X.X a evaluation 'XX, million we and $X.X compared million 'XX. had million.At

QX X-year level QX FY and utilization working of highest $XX we FY finish cash to to period.Given be we to So balances of in will expect million 'XX, flow a managing million our see million utilized capital, year 'XX. aggregate cash of the having to over $XX exhibited $XX of the the payments timing in we and continue exiting $XX range with the expect to an cash cash million, of positive

cash believe have fiscal of cash first year expected end the historically building balances is to We quarter has towards throughout during sufficient FY on of with guidance. highest the positive fiscal we the to utilization execute strategic now fiscal the than move our our that cash to flow As the initiatives have of year. the been case, we to more cash generating as remainder 'XX.Turning

be the We be revenue will $X.XX continue adjusted the share of FY and that to 'XX of expect loss million year to we in to $X.XX. in anticipate million, to per full range $XXX range $XXX

respectively, reminder, of this excluding revenue divested recently pro $XXX.X a to per FY for forma 'XX. a the share, and $X.XX, compares and assets of As million loss loss

margin gross XX% 'XX X%. FY of growth expect range the gross expect pro Tech range Med We to be to of to revenue FY 'XX X% in 'XX margin forma XX.X%.We XX% XX% of compared Device the to to XX% in range FY in and revenue the growth of Med

Med in a of Med XX% gross to expect gross in XX%.We're customers. transition range on Tech focus range We of to the XX% continuing margins margins our delivering to company the and to global our value Device with XX%

our on a team We back company thank rates at also here we're hard for exhibits strategy first investors and our it work expect grow looking year I'd expectations.Finally, fiscal 'XX.With believe improving will to forward their further and cash a And generation. those understand that Jim. to and be like that, profitability executing I'll at to turn commitment, to against quarter strong that we attractive AngioDynamics and us our while delivering execution that

James Clemmer

with passed have And our the I, many up sadly job Matt few and knowing of for operator, open Steve. and Steve did ago. and will you an as open missed, AngioDynamics Matt us a enjoyed we person. could before for words. many our pleasure to and several KeyBanc away particularly weeks to his here Matt offer Like up Mishan, we as the following company a had for call both an his call colleagues, Brett.Now all questions, and I'd please of the of working you, questions. analyst like of unexpectedly you excellent at say condolences family be Thank and years, him, who truly

Operator

[Operator James. today line Jayson Raymond from comes Instructions] Bedford question And our of the first with

Jayson Bedford

other prostate? NanoKnife growth to out it could use strong. break And mostly areas? seeing quite you Or is are use in I versus start seeing the internationally, business. are if in internationally. was on just wondering U.S. you Maybe you

James Clemmer

Jayson, we're no, in both. seeing actually, it

some track the refer establishing really some done in team. that different treat. ] [ relationships had the They've we And upgraded internationally than July a the I'll for has job the back that great team of organs announced we prostate been U.K. There's head physicians. So U.S. then we -- to international a call strong status had NICE QX, our with had the we start

in think Jayson. other So that Europe, areas we also has knock-on effect within a

work Europe you continue we're with So and down? break a do in going grow have our [indiscernible]. clinicians Steve, to to

Stephen Trowbridge

strong saw then in growth geographies. And a we both Yes. Jayson,

was So NanoKnife growth for our in the was growth disposable XX%. XX%. And markets, U.S., the in international about disposable

ocean. we've seen both of really So sides growth, the strong

Jayson Bedford

stuck Okay. first little On seems kind like And stabilizing there. may you should have And mechanical to a apologize, a thrombectomy, Can I in as to missed also give growth us think you second-gen the AlphaVac you seem AngioVac. I indication in product. to just timing why I be improve gear. still of it's AlphaVac? alluded

James Clemmer

X at have trick of other we're actually that how the time products completing you a good No, pace. indication. with the at XX% are want confident in, gaining the obviously, from PERT we're the it's need PE because growing who really the a soon.Second, really many X we already physician strong. acknowledged love same I AngioVac talking an And which work great what us, it that the and it, they've is does today, enrollment, we're is are and we product the with way breakthrough feedback and of get and there ago line on that the being FDA fine. designation unmet X study them is there, APEX many, things: used for the important was to communicated The area works Jayson, it. we or physicians Again, PE device AlphaVac, weeks the announced fit try can design AngioVac, saw to think

the got pleased those product. in of couple their of went years ago, indication.We're at I first take-up and think the they one a the that really of

next announce do couple launch year, have a that and morning, we this we enhancements of design Jayson. we'll did we -- calendar So

you'll those So see enhancements.

us. but that PE we We'll you is really, mid-calendar So for launch product. when -- feedback enhancements based have have within to have make design after indication, the it just FXX next a player, year gen, other to some first anatomy. be full also Anybody more the PE, AlphaVac we will clot next user-friendly, year a important that on confidence the year. about really little physician We'll and does not intuitive but removal just believe, major

Jayson Bedford

the enhancements And require Jim, does design an additional filing?

James Clemmer

No. These are simple enhancements.

I file done pretty that's letter I'm as think current my design. for just but they've team, a it let know. to answering the to We'll Again, sure Jayson. our regulatory you I'm case,

Jayson Bedford

you Okay. I'll seen in let And placement growth in. others jump of just for capital don't driven? you or and terms a capital, give bolus Auryon, get Can lot realize you're -- the I a but have it the upfront is sale? is this an update you installed On in seeing, And Or procedure then just us base? strong. lastly, the

Stephen Trowbridge

Yes.

Jayson, placements, the new So this of for lasers volume from have about talked volume finished moving we But we've last and of of shifting in them about net to in of also, the as seen a from terms users. placements where XX we past, lot lower the some the year. users quarter higher were

of the the -- customers shifting customers. with quarter XX but but seen.So that, around focus we've going that bit driving were we've also going new lower to and from to been last with total we're maybe of and talked some the goes significant end of we we along there's that's what the in to year, we right on new finished field. the systems back a buying lasers That's then utilization, net little utilization year, XXX from cash as higher-performing a pare the on performing that about lasers finding those number So

Operator

Steve Oppenheimer. next of from the with is Our question Lichtman line

Steven Lichtman

Just performance there? give of What could provide U.S. performer you what us coming and Can growth wondering you that? has on any quarters you seeing outside the in more little how overall. in the could international your a detail like And on is been It a ground sounds that business on years? key if look like visibility the that are NanoKnife sustainable

James Clemmer

was going The sustainable. a to know symposium the throughout But have it job. We're don't support NanoKnife, training Carlo number I where and it's procedures. they're their have data and That clinical our their did of that network expect course team I presenting our in Monte of partner strong think we compelling. experiences lot fourth if of to really also the -- Steve, end is get in year. the number our a at with great clinical month, this and cases highly we physicians a during QX. on

as things competitors So we've try at too. Solero our I expect is Steve. think by year. also got Nano, grow getting Solero this of gets to the great We've and I think side.So as also of happening, stronger quarters. most know, in effect We're good the effective we're the got more you some a know are U.S., of But lot rate going if the working don't next It's during same couple the here I we're growth just the see up that year. data we prior a higher there. space. a our happening.You that which in give we microwave the growth also We doctors a next side recognized adopt it wrap hope submit also lot the summer, PRESERVE, to U.S. with, our next But U.S. seeing done rate. still to mechanism Solero out that. to well get doctors We NanoKnife have utilizing think, indication to as a it, and tool knock-on works, that little here of strong in collection things widely be with action, growth as even will how and internationally then it on

Steven Lichtman

Auryon calendar it. DVT, Got vessel And year you small 'XX. reiterated then

we any that -- some anything there some Can You using docs DVT? in vessel of sense on expect single-center about small are field. in talked customer customers data getting a is from from or you're the those that your it from --

James Clemmer

research for on anecdotes, hear what published DVT. our you'll see customers market sure any a in R&D excited where addition testing has we're aspiration on our in product prior we get think good We launch. the the anything the confident I it that the the in own break really And on and -- about so vessel our internal not We're launch. we're free process. But XXXX. is what to to internal some significant.So and I but Auryon the laser focused device small prior doctors see it too, how job of in data can In way focus today really are it Steve, wouldn't our we're to does. don't believe areas the testing, a clock, really, different always works. does to does ready we good disrupt our our aspiration, their really by research, There's up if to people shown, to expect try that continue do are found meantime, going to

Steven Lichtman

gross just lastly, again, of as balancing top Got I thinking it. the about about thinking you're on thinking think to the then potential you So about balancing some how that we potential the you X business, line, company? the thinking should those divestitures additional you things? overall benefits be line product about And mentioned margin benefits Devices sales cash versus, just ahead? Med those additional of Or are Jim, products how provide are

James Clemmer

segment as the invest in We the ports. cash the A about what role we highlighted the to today, stability our house. does an other Tech the and couple portfolio love terrific Device our active grow businesses. Med in talked does. We've a we of that really business of providing And we as manager our Med always us But side things. mentioned job

that #X market compete company is The great Here company. really in great a a company. against strong, we

Our the small better, our we're is team strong.So our ports categories here, and we're versus going and like better company Goliath, although continue are is to guy win David to ports. in

provides Our it PICCs and will that. always midlines did we business, good well a today. balance But Steve. be really the us as like it's We know a battle, well.

we revenue. ago talked to the Tech years Let's transformation go our first XX% of we our back was that Tech Med into business X when only want about be.Med

X/X of it Now revenue. about you see our

device cash the good on has change. still mix But over reliant and less be we'll could today, stability. grow, to time we continues that a that think as it So

Operator

of Our Canaccord next from Young with is line Genuity. question the John

John Young

just Med takes year the fiscal know number guide to a end just margin gross Med for the but here feels a you on bit was for Tech and XX% for puts conservative. I see. from It margin. us specifically, Med guidance on high the about great First Tech? gross it the you the talk Tech of to Can on

Stephen Trowbridge

Yes.

about.So those are good overall coming about those a margin chewed that this by bit So the talked business, back tailwinds Angio thrombectomy also pulling we've are little us about, on to margins. field mix comprise revenue brand-new all mechanical put you're the business, lasers of Auryon gross business the we've as is about, kind the long-term talked we've seen, pressures for then but trying kind margin be with see gross the seen we And on accretion the with overall larger that Tech for a our in of continued shift on bit we talked both inflationary shift Jayson pretty things Med gross at our up to we've of little overall supportive talked corporate as that products those of in specifically, margin. be of level lasers shift base. the driving on be have sales that you've as going being the a and going Med right, of that, stabilize, Tech seen Tech of to the We've increase gross increased to Med it some NanoKnife, going from strategy John, those portion side as as utilization

John Young

bit And slide, by for now space guided then Have to It complete 'XX. get on patients early getting a the ongoing other in saw the like feels there. APEX, enrollment it's I calendar now, on the Great. a of studies ability the PE too, enrolled? impacted push

James Clemmer

No, Jim. so. it's think I don't John,

an we take look XX-month we there's we I window, leader, market believe, few nothing from I think years in back when think start field. took think if finish, a it's you else which at enrollment the we'll a ago is when about started look I at finish and what you go to if the think, and when they enrollment, to

it out little and be in that challenging, a were might knowing be there. a thought behind third we'd coming we was We X So initially. other probably players the little cautious it

to building peers And next outcomes in the building, finish and John. great it, but wait way.So We're the we product. internally really to there's it right is a think momentum work and year, had get pleased I of outcomes physicians, now. great we talked the their lot use schedule. the I with on can't that along what do some momentum we'll about the fits label shared think projected, It

it good novel have we'll them, now, into products we other because a we're but And in. bringing is with space will harder third probably for question it good others. be speculate unique device I X a Your that for a can't be is there. space one

really people we So we'll think give choice. a

John Young

last it if sneak And just I Great. my one could in. maybe

allocation. capital the on Just strategy on

stock given Just on balance the buyback thoughts strength of and current price? the stock sheet your

James Clemmer

talk that I conversations with Yes. Steve our about Board. we and and a have lot,

utilization will gave given you after the if think we to of people that given And be this our guidance, a to hit out end has QX, strong ago the sheet. market year the of hey, kind a where our time by we Steve same the a want external investors really where back today, have They think for say, have as take disruptions guidance I and we that Steve cash a want year. second. look year. to gone, we balance things

a talk there's at cash. a a today, that, around ensure be strong well. view And a utilize a disconnect We We'll think to have our we some disconnect. in about looking take while. with the We look as balance at. to we -- a sheet really we're good good we balance we're in We'll point, cash always have.We we're I'm do So investments conversation that the have position it with sure good at will strong a want share value that a sheet stable their also buyback. a who for investors get to want believe we but

Operator

turn I'd any Mr. Clemmer now to the Mr. closing over call to remarks. like for back Clemmer?

James Clemmer

to all and you, thanks employees. Thank our of AngioDynamics operator, again

by look our and this differentiated day.I tremendous products patient to our the technology We forward Thank transformation wellness meaningful science a one when at here, with our are QX. our you provides highly you. in to and Thanks are speaking on enabled to is again utilized. every to employees our occur changing that who outcomes company end of

Operator

conclude will today's This conference.

disconnect participation. at time, You may this and now you for thank your lines your

AngioDynamics (ANGO) 4 Oct 232024 Q1 Earnings call transcript